Aurora Cannabis Comforts Its Investors For Better Fiscal Results By 2023

For Aurora Cannabis, it has been experiencing declining sales for the last few quarters. It has also failed to meet its targets for profitability. The company’s Q1 revenue declined to 47.71M US dollars from the same period a year ago. The drop in consumer cannabis revenue was also significant. This is mainly due to the company’s lack of effort in developing high-margin derivatives. In October 2019, Canada launched the derivatives market, which was referred to as “Cannabis 2.0.”

Aurora Cannabis

Although, the company aims to hit its target of getting full EBITDA by 2023. Aurora Cannabis is a Canadian producer and distributor of marijuana and derivatives. It also conducts various activities related to the production and distribution of marijuana. Aside from producing dried marijuana, the company also sells capsules, oils, and topical products for medical use. It also offers vaporizers and herb mills. It also runs a network of outreach centers for the benefit of patients. It offers various services such as patient counseling, design and construction services, and analytical testing. The company’s other brands include CanniMed, Daily Special, AltaVie, Aurora, MedReleaf.